Teva Pharmaceutical Industries Limited

NYSE:TEVA

Drug Manufacturers - Specialty & Generic

Healthcare
$42.23 -3.35%

-$1.09 today

Market cap
$49.28B
Beta
0.85
P/E (TTM)
23.1
EPS (TTM)
$1.36
52W Low $14.99High $37.35

Volume 8.86M

Average 6.22M

TEVA Weighted Avg Shares

Average number of basic shares outstanding during the period, used to calculate basic EPS.

Teva Pharmaceutical Industries LimitedNYSE: TEVA

Weighted Avg Shares · Q2 FY2026 · quarter ended Jun 2026

Weighted avg shares grows in line with its trailing trend

Q2 FY2026 weighted avg shares of 1.17B shares rose 1.6% year over year, in line with the +1.5% change in trailing-twelve-month weighted avg shares. Sequentially, it rose 0.8% from the prior quarter. Over 3 fiscal years it compounded at +1.2% a year.

Context

  • Weighted avg shares increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +1.6% holds above the trailing-twelve-month pace of +1.5%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterJun 2026
1.17B+0.8% QoQ
Last fiscal yearDec 2025
1.15B+1.6% YoY
LTMJun 2026
1.15B+1.5% YoY
Weighted Avg Shares past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+1.6%——
1 year+1.6%——
3-year CAGR+1.2%——
5-year CAGR——
10-year CAGR——

Weighted Avg Shares history

Shares · from the income statement

Latest · FY2025
1.15B USD
Year-over-year change
+1.6%
4-year CAGR
+1.0%

Weighted Avg Shares vs competitors

How TEVA compares with its peers on the latest reported figures

  • TEVA's LTM Jun 2026 weighted avg shares of 1.15B shares is the 2nd highest of the 5 companies compared; the peer median is 574.59M shares.
  • Its year-over-year change of +1.5% is the 3rd highest of 5, against a peer median of +0.8%.
  • Over three fiscal years its annual growth of +1.2% compares with a peer median of +6.1%.
TEVA Competitors Peer median
Weighted Avg Shares for TEVA and competitors
Company Period LTM YoY 3-year CAGR
VTRSViatris Inc.LTM Jun 20261.16B -2.4%-1.2%
TEVATeva Pharmaceutical Industries LimitedLTM Jun 20261.15B +1.5%+1.2%
RDYDr. Reddy's Laboratories LimitedLTM Sep 2026833.5M +0.1%+0.1%
AMRXAmneal Pharmaceuticals, Inc.LTM Jun 2026315.69M +1.5%+27.6%
ALVOAlvotechLTM Mar 2026297.74M +6.2%+12.2%
Peer median (excluding TEVA) 574.59M+0.8%+6.1%

Competitors are the stored peer set for TEVA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue15.88B14.93B15.85B16.54B17.26B
Cost of Revenue8.28B7.95B8.2B8.48B8.32B
Gross Profit7.59B6.97B7.65B8.06B8.94B
Gross Margin47.8%46.7%48.2%48.7%51.8%
Research & Development1.09B838M953M1.06B1.01B
Selling, General & Admin3.53B3.45B3.5B3.7B3.97B
Operating Expenses5.88B9.17B7.21B8.37B6.78B
Depreciation & Amortization1.33B1.31B1.15B1.06B1B
EBITDA4.41B(925M)1.56B4.43B3.14B
EBITDA Margin27.8%-6.2%9.8%26.8%18.2%
Operating Income1.72B(2.2B)433M(303M)2.16B
Operating Margin10.8%-14.7%2.7%-1.8%12.5%
Interest Income0068M00
Interest Expense891M930M1.03B941M916M
Other Income / Expenses(1.05B)(945M)(1.06B)(980M)(919M)
Income Before Tax667M(3.14B)(622M)(1.28B)1.24B
Pre-Tax Margin4.2%-21.1%-3.9%-7.8%7.2%
Income Tax Expense211M(643M)(7M)676M(180M)
Net Income417M(2.45B)(559M)(1.64B)1.41B
Net Margin2.6%-16.4%-3.5%-9.9%8.2%
EPS (Basic)0.38(2.20)(0.50)(1.45)1.23
EPS (Diluted)0.38(2.20)(0.50)(1.45)1.20
Weighted Avg Shares1.1B1.11B1.12B1.13B1.15B
Weighted Avg Shares (Diluted)1.11B1.11B1.12B1.13B1.17B

Teva Pharmaceutical Industries Limited

NYSE:TEVA

Intrinsic Alpha fair value

Locked

Current Price

$42.23

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.